- Document Number:
20240424017
- Appl. No:
18/750592
- Application Filed:
June 21, 2024
- Abstract:
A method of inducing expression of aquaporin-4 by providing a bioconjugate having a quantum dot bound to human erythropoietin and contacting human astrocytes with the bioconjugate, which induces expression of aquaporin-4. A composition having a bioconjugate having a quantum dot bound to human erythropoietin. A method of providing a quantum dot and forming a bioconjugate by depositing human erythropoietin onto the surface of the quantum dot.
- Assignees:
The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, VA, US)
- Claim:
1. A method of inducing expression of aquaporin-4, the method comprising: providing a bioconjugate comprising a quantum dot bound to human erythropoietin; and contacting human astrocytes with the bioconjugate, thereby inducing expression of aquaporin-4 by the human astrocytes.
- Claim:
2. The method of claim 1, wherein the quantum dot comprises a cadmium selenide core; an inner cadmium sulfide shell in contact with the cadmium selenide core; and an outer zinc sulfide shell in contact the inner cadmium sulfide shell.
- Claim:
3. The method of claim 1, wherein the quantum dot is a gold nanoparticle, a non-gold metal nanoparticle, or a liposome.
- Claim:
4. The method of claim 1, wherein the quantum dot comprises a solubilizing ligand.
- Claim:
5. The method of claim 4, wherein the solubilizing ligand is N-(2-carboxyethyl)-N-[2-[(6,8-dimercapto-1-oxooctyl)amino]ethyl]-β-alanine.
- Claim:
6. The method of claim 1, wherein the human erythropoietin comprises a poly-histidine tail.
- Claim:
7. The method of claim 1, wherein the quantum dot has from 2 to 40 molecules of the human erythropoietin deposited thereon.
- Claim:
8. A composition comprising: a bioconjugate comprising a quantum dot bound to human erythropoietin.
- Claim:
9. The composition of claim 8, wherein the quantum dot comprises: a cadmium selenide core; an inner cadmium sulfide shell in contact with the cadmium selenide core; and an outer zinc sulfide shell in contact the inner cadmium sulfide shell.
- Claim:
10. The composition of claim 8, wherein the quantum dot is a gold nanoparticle, a non-gold metal nanoparticle, or a liposome.
- Claim:
11. The composition of claim 8, wherein the quantum dot comprises a solubilizing ligand.
- Claim:
12. The composition of claim 11, wherein the solubilizing ligand is N-(2-carboxyethyl)-N-[2-[(6,8-dimercapto-1-oxooctyl)amino]ethyl]-β-alanine.
- Claim:
13. The composition of claim 8, wherein the human erythropoietin comprises a poly-histidine tail.
- Claim:
14. The composition of claim 8, wherein the quantum dot has from 2 to 40 molecules of the human erythropoietin deposited thereon.
- Claim:
15. A method comprising: providing a quantum dot; and forming a bioconjugate by depositing human erythropoietin onto the surface of the quantum dot.
- Claim:
16. The method of claim 15, wherein the quantum dot comprises: a cadmium selenide core; an inner cadmium sulfide shell in contact with the cadmium selenide core; and an outer zinc sulfide shell in contact the inner cadmium sulfide shell.
- Claim:
17. The method of claim 15, wherein the quantum dot is a gold nanoparticle, a non-gold metal nanoparticle, or a liposome.
- Claim:
18. The method of claim 15, wherein the quantum dot comprises a solubilizing ligand.
- Claim:
19. The method of claim 18, wherein the solubilizing ligand is N-(2-carboxyethyl)-N-[2-[(6,8-dimercapto-1-oxooctyl)amino]ethyl]-β-alanine.
- Claim:
20. The method of claim 15, wherein the human erythropoietin comprises a poly-histidine tail.
- Claim:
21. The method of claim 15, wherein from 2 to 40 molecules of the human erythropoietin are deposited onto the quantum dot.
- Current International Class:
61; 61; 61; 61; 61
- Accession Number:
edspap.20240424017
Processing Request
No Comments.